Big Biopharma Trails Behind The Market: JP Morgan's 2025

Dec 22, 2024 · Biopharma stocks gained 9.6% in 2024, trailing the S&P 500’s 28.5% rise. Eli Lilly projects double-digit revenue growth through early 2030s, and Bristol-Myers expects $10B in …

6%
OFF

Big Biopharma Trails Behind The Market: JP Morgan's 2025

2 weeks from now

Dec 22, 2024 · Biopharma stocks gained 9.6% in 2024, trailing the S&P 500’s 28.5% rise. Eli Lilly projects double-digit revenue growth through early 2030s, and Bristol-Myers expects $10B in …

benzinga.com

35%
OFF

Biopharma Industry Eyes 2025 Bounceback, Grapples With …

2 weeks from now

22 hours ago · Morgan Stanley estimates that around $175 billion of 2025 U.S. large-cap biopharma revenue – 35% of the total – will go off patent by the end of the decade. ... Browse …

reuters.com

$25
OFF

JPM25: BMS, Pfizer And Merck CEOs Address Key Patent Cliffs And …

2 weeks from now

1 day ago · Of all of the upcoming patent losses in biopharma, none match up to Keytruda, the industry’s sales king in 2023. The immuno-oncology megablockbuster generated $25 billion in …

fiercepharma.com

$3
OFF

The Biopharma Outlook For 2025: Opportunities And Challenges

2 weeks from now

Jan 8, 2025 · For example, 2024’s biopharma IPO market began promisingly with $3.6 billion in total funding in Q1 – the highest in several years – but fell to $1.6 billion across Q2 and Q3 …

pharmaphorum.com

39%
OFF

Vertex Leads J.P. Morgan's Top Biotech Picks List For 2025 - MSN

2 weeks from now

J.P. Morgan added that its buyside survey showed that 39% of respondents expect biotech to outperform the broader market in 2025, while 23% expect it to underperform. More on …

msn.com